Intellia rises after US FDA lifts clinical hold on heart disease gene therapy trial

INTELLIA THERAPEUTICS

02/03/2026 13:05

** Shares of gene therapy developer Intellia Therapeutics NTLA.O rise 4.8% to $14.44 premarket

** Co says the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a heart disease

** Last year, the company said the FDA paused its two main late-stage trials for the gene-editing treatment, nexiguran ziclumeran, after a patient died from severe liver complications

** In January, the FDA removed its clinical hold on one of the trials, MAGNITUDE-2, after the company took mitigation measures such as enhanced monitoring of liver laboratory tests and the exclusion of patients with certain liver abnormalities

** The therapy is being tested in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a serious and worsening heart disease in which an abnormal protein builds up in the heart, making it stiff and less able to pump blood properly

** NTLA rose 53.3% in 2025

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))